NCT07467993RecruitingPhase 2
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
A Phase 2a, Randomized, Participant- and Investigator- Blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With DSM-5 Schizophrenia (STAR-1)
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 142 (estimated)
- First submitted
- 9 Mar 2026
- Start date
- 16 Mar 2026
- Primary completion date
- 29 Jul 2027
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Schizophrenia
- NCT number
- NCT07467993
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 142
- From 16 Mar 2026 to the primary completion date, 29 Jul 2027
- 15 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any primary DSM-5 disorder other than schizophrenia within 12 months before screening (confirmed using Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) at screening)
- History of treatment resistance to antipsychotic medications defined as inadequate response to two adequate courses of pharmacotherapy or previous clozapine treatment for treatment-resistant schizophrenia
- Participants who need to be treated with drugs that are known to be moderate and strong CYP3A4 inhibitors and inducers will be excluded
- Participants taking a long-acting injectable antipsychotic could not have received a dose of medication in the last 12 weeks (24 weeks for INVEGA TRINZA®) before baseline
- Other protocol-defined inclusion/exclusion criteria may apply
Who the study is looking for
- Participant is aged 18 to 65 years, inclusive, at screening
- Participant is capable of providing informed consent
- Participant has a primary diagnosis of schizophrenia, established by a comprehensive psychiatric evaluation based on the DSM-5 (American Psychiatric Association 2013) criteria and confirmed by Structured Clinical Interview for DSM-5 Clinical Trials version (SCID-5-CT)
- Participant is willing and able to be confined to an inpatient setting for the study duration (except for the follow-up period), follow instructions, and comply with the protocol requirements
- Participant is experiencing an acute exacerbation or relapse of psychotic symptoms, with onset less than 2 months before screening
- The participant requires hospitalization for this acute exacerbation or relapse of symptoms
- If already an inpatient at screening, has been hospitalized for less than 2 weeks for the current exacerbation at the time of screening
- Positive and Negative Syndrome Scale total score between 80 and 120, inclusive, at screening a. Score of ≥ 4 (moderate or greater) for ≥ 2 of the following Positive Scale (P) items:
- Item 1 (P1; delusions)
- Item 2 (P2; conceptual disorganization)
- Item 3 (P3; hallucinatory behavior)
- Item 6 (P6; suspiciousness/persecution)
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (15)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Investigative Site Coordinator of this site? Confirm its status | Haskovo | Bulgaria | Recruiting |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Kazanlak | Bulgaria | Recruiting |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Lovech | Bulgaria | Recruiting |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Plovdiv | Bulgaria | Recruiting |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Sliven | Bulgaria | Recruiting |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Sofia | Bulgaria | Recruiting |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Veliko Tarnovo | Bulgaria | Recruiting |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Vratsa | Bulgaria | Recruiting |
| Pillar Clinical Research LLC Coordinator of this site? Confirm its status | Bentonville | United States | Recruiting |
| Uptown Research Institute, LLC Coordinator of this site? Confirm its status | Chicago | United States | Recruiting |
| Pillar Clinical Research LLC Coordinator of this site? Confirm its status | Chicago | United States | Recruiting |
| CenExel iResearch Coordinator of this site? Confirm its status | Decatur | United States | Recruiting |
| Segal Institute for Clinical Research Coordinator of this site? Confirm its status | Miami | United States | Recruiting |
| CNRI-Los Angeles, LLC Coordinator of this site? Confirm its status | Pico Rivera | United States | Recruiting |
| Arch Clinical Trials, LLC Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.